Quest Diagnostics Incorporated (DGX) Up 6.0% — Buy Before It Runs Further?
Key Points
Quest Diagnostics Incorporated (DGX) surged 6.01% in the latest session, advancing to $208.11 after closing the prior session at $196.31. The move translates to a gain of $11.80 in a single day, underscoring strong performance as the stock quickly regained ground and pushed deeper into its recent trading range. With buyers firmly in control, DGX spent the session in rally mode and finished near the upper end of its latest push, reinforcing the current momentum on the NYSE.
Trading volume came in at 550,592 shares, running below the 90-day average of 965,341. Even with lighter-than-typical participation, the upside follow-through was notable, suggesting the advance didn’t require outsized turnover to gain traction. From a longer-term perspective, DGX is now within $5.39 of its 52-week high of $213.50, sitting about 2.5% below that peak set on 02/27/2026. That proximity keeps the stock in striking distance of a breakout level that many investors watch for confirmation of sustained strength.
In the broader Health Care landscape, DGX’s jump stood out as a clear show of relative strength alongside large-cap names such as HCA Healthcare (HCA), Cencora (COR), and McKesson (MCK). With the stock pressing toward its annual high and posting a decisive one-day move, DGX is signaling an advancing trend that remains constructive for momentum-focused investors monitoring the next test of resistance.
Why Quest Diagnostics Incorporated Price is Moving Higher
Quest Diagnostics (DGX) has attracted fresh investor enthusiasm after a cluster of shareholder-friendly announcements helped offset a mixed news tape. The company lifted its quarterly payout by 7.5% to $0.86 per share (an annualized $3.44), extending a 15-year streak of increases, and expanded its share repurchase authorization by an additional $1 billion—leaving roughly $1.4 billion available. Taken together, the higher cash return and a larger buyback “bid” can reinforce bullish sentiment by signaling management confidence in cash generation and by supporting per-share metrics over time. That catalyst helped keep momentum building even as the stock saw elevated short-term volatility.
Fundamentals have also contributed to the upbeat tone. Quest’s Q4 revenue rose to $2.81 billion, up 7.1% year over year, and full-year revenue reached $11.04 billion, up 11.8%, supported by an 8.98% profit margin. Management’s outlook for 2026—$11.70 billion–$11.82 billion of revenue and adjusted EPS of $10.50–$10.70—added another favorable development for investors looking for steady, defensive health care growth. Analyst revisions from Leerink Partners captured the same push-pull: a modest near-term EPS trim, but higher forecasts stretching from FY2025 through FY2028, which can encourage longer-horizon positioning. While a prior director sale created some selling pressure, the market’s focus has remained on capital returns and the stronger multi-year earnings trajectory.
What is the Quest Diagnostics Incorporated Rating - Should I Buy?
Weiss Ratings assigns DGX a B rating. Current recommendation is Buy. In practical terms, that places Quest Diagnostics Incorporated in the upper tier of risk-adjusted opportunities, where business quality and steadier fundamentals tend to matter as much as near-term momentum. For investors looking for a Health Care name with a more balanced profile, a B (Buy) rating signals favorable positioning without needing everything to go perfectly.
The sub-index picture helps explain the appeal. The Good Growth Index aligns with steady operational progress, supported by 7.06% revenue growth and an 8.98% profit margin. The Good Efficiency Index also fits with a 14.75% return on equity, indicating the company has been able to generate solid returns on shareholder capital. Valuation is part of the equation too: a forward P/E of 22.39 implies the market is already paying for quality, but that can be reasonable when the broader risk/reward setup remains favorable.
On the risk side, balance-sheet strength stands out. The Excellent Solvency Index is a key support for the overall B rating, helping offset the usual uncertainties that come with a large, mature Health Care business. Meanwhile, the Good Volatility Index and Good Total Return Index point to a profile that has been more investor-friendly than many peers on a risk-adjusted basis.
Within the Health Care sector, DGX is on par with HCA Healthcare, Inc. (HCA, B) and Cencora, Inc. (COR, B), while trailing McKesson Corporation (MCK, B+). Overall, DGX looks competitively positioned among higher-quality sector names, with solvency strength providing an added margin of comfort.
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated (DGX) is a leading provider of diagnostic information services in the Health Care sector, supporting clinicians, hospitals, health systems, employers, and patients with testing and insights used across prevention, diagnosis, and treatment decisions. The company operates a broad laboratory network and patient service infrastructure that helps move specimens efficiently from collection to analysis, with an emphasis on quality processes, standardized workflows, and consistent turnaround. Quest’s scale and reach also support convenient access for consumers through widely available patient service centers, making routine testing and chronic-condition monitoring easier to integrate into everyday care.
Quest offers a wide menu of clinical laboratory tests spanning core areas such as routine blood chemistry, infectious disease testing, cardiometabolic and endocrine assessment, oncology and anatomic pathology, and women’s health. It also provides advanced diagnostics, including genetics and specialized esoteric testing, as well as services that help coordinate care—such as test utilization support, data connectivity with provider systems, and tools that integrate results into clinical workflows. That combination of breadth and operational execution positions Quest as a key partner for organizations looking to manage population health, improve access to testing, and streamline diagnostic pathways across diverse care settings.
Investor Outlook
With a Weiss Rating of B (Buy), Quest Diagnostics Incorporated (DGX) appears favorably positioned for potential continued gains if momentum holds and key technical levels remain intact. Investors may watch follow-through versus recent breakout areas, along with broader Health Care trends that can influence defensive demand and sentiment. Over time, the durability of the B (Buy) profile will hinge on sustaining the factors that support its overall risk-adjusted standing. See full rankings of all B-rated Health Care stocks inside the Weiss Stock Screener.
--